Assignee
ELIXIRGEN THERAPEUTICS INC
US·6 granted patents·5 pending applications·12 citations·filing 2014–2024
Top patents by PatentIndex Score
11 records- 0196US11421248B2Temperature-based transient delivery of nucleic acids and proteins to cells and tissuesELIXIRGEN THERAPEUTICS INC·Filed 2021·Granted Aug 23, 2022·3 cites·20 claims
- 0291US10744183B2Methods of using ZSCAN4 for rejuvenating human cellsELIXIRGEN THERAPEUTICS INC·Filed 2014·Granted Aug 18, 2020·6 cites·10 claims
- 0385US11389504B2Methods of using ZSCAN4 for rejuvenating human cellsELIXIRGEN THERAPEUTICS INC·Filed 2019·Granted Jul 19, 2022·3 cites·18 claims
- 0484US12478659B2Methods of using ZSCAN4 for rejuvenating human cellsELIXIRGEN THERAPEUTICS INC·Filed 2023·Granted Nov 25, 2025·0 cites·8 claims
- 0582US12478657B2Methods of using Zscan4 for rejuvenating human cellsELIXIRGEN THERAPEUTICS INC·Filed 2022·Granted Nov 25, 2025·0 cites·23 claims
- 0680US2025027111A1Temperature-based transient delivery of nucleic acids and proteins to cells and tissuesELIXIRGEN THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0778US12060568B2Temperature-based transient delivery of nucleic acids and proteins to cells and tissuesELIXIRGEN THERAPEUTICS INC·Filed 2022·Granted Aug 13, 2024·0 cites·36 claims
- 0869US2025332239A1Antigens for cancer immunotherapyELIXIRGEN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0968US2025140424A1Cell therapy protocol systems and methodsELIXIRGEN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1061US2024350605A1Temperature-controllable, rna immunotherapeutic for cancerELIXIRGEN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1160US2024269268A1Temperature-controllable, self-replicating rna vaccines for viral diseasesELIXIRGEN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ELIXIRGEN THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →